🔎 Trials Near Me

Home › Lymphoma › Massachusetts › Boston

Lymphoma clinical trials in Boston, MA

33 studies for Lymphoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

RecruitingPhase 1
  • Beth Israel Deaconess Medical Center - Research, Boston
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07192471

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07015242

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

Recruiting
  • Mass General Hospital, Boston
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07013435

Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors

Recruiting
  • Mass General Brigham, Boston
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07014293

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

RecruitingPhase 1/2
  • Dana Farber Cancer Institute., Boston
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610

Epco, Zanu, Ritux for R/R FL or MZL

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06563596

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

RecruitingPhase 1/2
  • Research Site, Boston
  • Research Site, Boston
Ages 12 and older · All sexes · Updated Sep 14, 2026 · NCT06137144

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

RecruitingPhase 4
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07426484

The CARDIOPROTECT Trial

RecruitingPhase 2
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT07654426

DALY II USA/ MB-CART2019.1 for DLBCL

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

RecruitingPhase 1/2
  • Call for Information (Investigational Site 0026), Boston
6 Months – 17 Years · All sexes · Updated Jul 6, 2026 · NCT02332668

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

RecruitingPhase 1/2
  • Dren Investigational Site, Boston
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

RecruitingObservational study
  • Dana-Farber Cancer Institute, Boston
All ages · All sexes · Updated May 18, 2026 · NCT01790152

Remote Monitoring and Symptom Management Digital Application

Recruiting
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Apr 28, 2026 · NCT07553572

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Recruiting
  • Massachusetts General Hospital Cancer Center, Boston
Ages 18 and older · All sexes · Updated Apr 21, 2026 · NCT05646576

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

RecruitingPhase 1/2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Recruiting
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06923397

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

RecruitingPhase 2
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT06510309

Odronextamab in Low Tumor Volume Advanced FL

RecruitingPhase 2
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT07128641

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

RecruitingPhase 2
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT06510361

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

RecruitingPhase 2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT05800366

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

RecruitingPhase 2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT06854003

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

RecruitingPhase 1
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT06475235

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Recruiting
  • Brigham & Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT04368702

Avo In R/R And Previously Untreated MCL

RecruitingPhase 1/2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jan 21, 2026 · NCT04855695

Mosunetuzumab for CLL MRD Clearance

RecruitingPhase 1/2
  • Brigham & Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT07052695

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Dec 5, 2025 · NCT06986174

HEME Home Transfusion Program

Recruiting
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 17, 2025 · NCT06487247

About Lymphoma

Lymphoma is a cancer affecting the immune system. Hodgkins Lymphoma and Non Hodgkins Lymphoma are types of lymphoma. Learn about symptoms and treatments.

More about Lymphoma on MedlinePlus

Lymphoma trials in other cities

Other studies in Boston

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.